VIOL Medical, the RF microneedling manufacturer behind the well-known Sylfirm X system, signed a memorandum of understanding with Amorepacific — the Korean beauty giant — at the end of March 2026. Alongside the agreement, Amorepacific made a strategic investment in the company.
This is more than a distant piece of business news. When a global cosmetics giant chooses to invest specifically in a medical-aesthetic device maker, it signals where the entire market is heading. For clinics that operate — or are considering — energy-based devices, it is an important cue.
In brief
- Amorepacific, the Korean beauty giant, signed an MOU and made a strategic investment in VIOL Medical — maker of Sylfirm X
- The RF microneedling market is projected to grow from $1.6 billion to roughly $4.3 billion by 2035
- VIOL is having a breakout year: FDA clearance for CELLINEW, new indications in Taiwan, and a launch in Thailand
- Sylfirm X is distributed in Israel by Lee Daniels — and the manufacturer’s global backing keeps getting stronger
What happened? A deal that bridges cosmetics and medical devices
On March 27, 2026, the two Korean companies announced a formal collaboration. Under the memorandum of understanding, Amorepacific will combine its skincare and research expertise with VIOL Medical’s energy-based device (EBD) technology.
The agreement has three main components:
- Joint product development combining skincare and medical devices
- Marketing collaborations between the two companies
- A joint move into the at-home skincare device space
Beyond that, Amorepacific made a strategic investment in VIOL Medical — a move that signals long-term confidence, even though the investment amount was not disclosed. It helps to grasp the scale involved: Amorepacific is one of the largest beauty companies in the world, home to global brands such as Laneige, Sulwhasoo, and Innisfree.
VIOL Medical’s CEO, Eunchun Lee, summed up the direction: the companies will work together across every patient touchpoint — from the professional clinic to the consumer at home.
“Through this partnership with VIOL Medical, we aim to connect the professional treatment environment with everyday skincare at home.”
— Sean Kim, CEO of Amorepacific
Why does it matter for medical aesthetics?
$4.3 billion
The projected size of the global RF microneedling market by 2035 — annual growth of 10.3% from a base of $1.6 billion in 2025
This growth is driven by the ongoing shift of patients toward minimally invasive treatments with no surgical downtime. The deal reflects an even broader trend: the convergence of the cosmetics world and the medical device world.
The major cosmetics players understand that today’s consumer is no longer satisfied with a cream — they are looking for a treatment continuum that begins in the clinic and continues at home. South Korea, which already sets the global tone in K-Beauty and aesthetic devices, is the natural place where this convergence takes shape.
Do home devices threaten clinics? Quite the opposite. A home device will never replace a professional treatment at clinical intensities — but it produces more informed patients who understand the value of the technology and arrive at the clinic with expectations and knowledge.
For the clinic, that means the professional treatment becomes the anchor of a complete treatment continuum — diagnosis, in-clinic treatment, and guided at-home maintenance. Clinics that learn to build this continuum will increase both revenue per patient and return rates.
The trend is clearly felt in Israel as well. Demand for RF microneedling treatments — for acne scars, melasma, rosacea, and skin rejuvenation — is on a steady rise. Clinics that offer proven technology with strong international backing enjoy a clear competitive advantage, and those who also know how to retain patients over time turn that advantage into real growth.
It is worth noting a shift in Israeli patient behavior: they no longer walk into a clinic and ask “what do you have?” — they search for specific devices by name, after reading about them on social media and in online groups. Featuring a recognized, talked-about platform on your treatment menu has become a marketing tool in its own right.
A closer look: VIOL Medical — a year of global momentum
VIOL Medical, founded in 2009, focused from the start on a single niche: radiofrequency-based microneedling. The company’s portfolio includes Sylfirm X, Scarlet, CELLINEW, and DUOTITE.
How RF microneedling works — and why it captured the market
The technology combines two proven mechanisms: micro-needles that penetrate to a controlled depth in the dermis, and radiofrequency energy released through them directly into the tissue. The targeted heat creates microscopic zones of coagulation that stimulate renewed production of collagen and elastin — without damaging the epidermal layer above.
The clinical advantage is clear: because the energy bypasses the skin surface, the treatment is also suitable for darker skin tones and for the warm seasons — scenarios in which some laser devices are limited. Downtime is short, and the safety profile is high.
What sets Sylfirm X apart is its ability to work in two modes — pulsed wave and continuous wave — allowing the treatment to target both vascular and pigmentation concerns (such as melasma and rosacea) and skin tightening and rejuvenation, all on the same platform.
The Amorepacific agreement is just one link in a chain of developments in 2026:
- FDA clearance for the CELLINEW device in the U.S.
- New indication approvals for Sylfirm X in Taiwan
- The SYLFIRM X APAC symposium in Bangkok and the device’s launch in the Thai market
- A strategic investment by a global beauty giant
The picture that emerges is clear: a niche manufacturer becoming a global player with growing resources in development, regulation, and marketing. For physicians, that means the device in the clinic will continue to receive support, updates, and new indications for years to come.
Amorepacific’s investment is expected to accelerate the pace of development even further. Combining the research capabilities of a cosmetics giant with a clinical device platform opens the door to integrated protocols — an in-clinic treatment backed by a dedicated line of follow-up products — a model already proving itself in advanced markets.
What does it mean for your clinic?
The Sylfirm X — RF microneedling system, with its ability to operate in both continuous and pulsed wave to treat a range of skin concerns, is distributed in Israel by Lee Daniels. This news reinforces what leading clinics in Israel already know: this is a platform with some of the strongest industrial backing in the field.
When choosing aesthetic equipment, it pays to look beyond the technical spec sheet. Three signs point to a manufacturer worth betting on:
- Financial stability and a steady flow of investment
- A pace of regulatory approvals in key markets
- Ongoing academic activity and professional training
From a business standpoint, RF microneedling is one of the steady revenue engines of an aesthetic clinic: the treatment is delivered in a series of sessions, generates recurring and predictable income, and suits a wide range of patients all year round. A single platform that covers both pigmentation and vascular concerns and skin tightening increases the output of every treatment room.
It is worth remembering: even the best device in the world delivers results only in skilled hands. The success of the investment depends on staff training, on building the right treatment menu, and on pricing that reflects the value of the technology. That is why it pays to choose a distributor that also provides professional workshops and training, not just a box.
Lee Daniels, as an authorized distributor of medical aesthetic equipment (AMAR registration, ISO 9001:2015), stays with clinics after the purchase as well — with training, service, and professional support.
Frequently asked questions
What exactly was signed between Amorepacific and VIOL Medical?
A memorandum of understanding for the joint development and marketing of solutions that combine skincare and energy-based devices, alongside a strategic investment by Amorepacific in the company. The investment amount was not disclosed.
Does it affect Sylfirm X devices already operating in clinics?
Not immediately — but a stronger manufacturer means continued development, support, and new indications over time. That increases confidence in the investment in the device.
What is special about Sylfirm X’s RF microneedling technology?
The device combines micro-needles with radiofrequency energy in two operating modes — continuous and pulsed wave — and treats a wide range of skin concerns, including melasma, rosacea, scars, and skin rejuvenation.
How can I see the device in action in Israel?
Lee Daniels, the authorized distributor in Israel, holds demonstrations and professional training sessions. You can get in touch through the contact form on the website.
Source: Amorepacific, Viol Medical Sign MOU on Beauty and Medical Devices — PR Newswire
By: The Lee Daniels Team | Date: 06/07/2026
Want to hear more?
The Lee Daniels team would be glad to present Sylfirm X and build the treatment portfolio that fits your clinic together with you.
Lee Daniels — authorized distributor of medical aesthetic equipment in Israel